Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Altor in connection with the investment in H2 Green Steel
Mandate

Vinge advises Altor in connection with the investment in H2 Green Steel

August 30, 2022 Commercial Agreements Banking and Finance Corporate Crime & Compliance M&A Employment and Benefits Intellectual Property Environmental Law Real Estate and Construction

Vinge represents Altor Fund V in connection with its investment in H2 Green Steel. The investment has been carried out in connection with H2 Green Steel's series B round totalling approx. EUR 190 million. Investors participating in the capital raise included, in addition to Altor, inter alia AMF, GIC, Swedbank Robur Alternative Equity, FAM and IMAS Foundation.

H2 Green Steel was founded in 2020 with the ambition to accelerate the decarbonization of the steel industry, using green hydrogen. Steel, which is one of the world’s largest carbon dioxide emitters, is the company’s first business vertical. H2 Green Steel is headquartered in Stockholm, Sweden, with its first green steel plant under development in Boden, northern Sweden.

Vinge's team consisted mainly of Christina Kokko, Johan Larsson, Carl Fredrik Wachtmeister, Linus Adolfsson (M&A), Lisa Hörnqvist, Elis Allmark (Commercial Agreements), Johan Cederblad (Environment), Kristoffer Larsson (Real Estate), Julia Löfqvist (Compliance), Kamyar Najmi (Banking and Finance), Axel Lennartsson (IP), Ebba Svenburg (Employment), Sara Dahlros Sköld and Julia Hagelberg (project assistants).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025